Tokyo Tape
Sign in
← Suzuken

Quarterly report · Q1

9987.TEDINET S100OZ8T
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥553.8bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥2.24T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥541.1bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥3.5bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income−¥1.6bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥4.6bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥23.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥443m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥4.5bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax−¥479m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥2.7bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥14.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥414m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥2.7bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income−¥373m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥1.17Tat 2022-06-30Cons.Assets
Total assets¥1.14Tat 2022-03-31Cons.Assets
Total assets¥1.17Tat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥745.8bnat 2022-06-30Cons.Liabilities
Total liabilities¥723.7bnat 2022-03-31Cons.Liabilities
Net assets / equity¥419.3bnat 2022-06-30Cons.Net assets
Net assets / equity¥418.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥415.3bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥132.1bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥141.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥30.492022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.192021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.662021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio36.0%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio35.4%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥52.6bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥9.8bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥42.8bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥434m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥21.4bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥21.4bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥31m
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥533.5bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥519.6bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥13.8bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.4bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥11.5bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.9bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥8.6bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥587m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥618.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥553.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥65.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥3.5bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥41.9bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥9.8bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥32.1bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥644m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥21.9bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥21.9bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥323m
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥520.1bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥506.1bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥13.9bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2021-04-01 → 2021-06-30−¥3.2bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥11.3bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥3.3bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥7.9bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥468m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥595.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥541.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥54.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30−¥1.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 350
ItemContextValueUnit
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.1490
Number of shares held in own name treasury shares etcCurrentQuarterInstant15402300
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant15402300
Shareholding ratio treasury shares etcCurrentQuarterInstant0.1490
Cash and depositsPrior1YearInstant141377000000JPY
Cash and depositsCurrentQuarterInstant132052000000JPY
Notes and accounts receivable tradePrior1YearInstant518408000000JPY
Notes and accounts receivable tradeCurrentQuarterInstant534967000000JPY
Short term investment securitiesPrior1YearInstant60086000000JPY
Short term investment securitiesCurrentQuarterInstant67949000000JPY
Merchandise and finished goodsPrior1YearInstant130584000000JPY
Merchandise and finished goodsCurrentQuarterInstant135380000000JPY
Work in processPrior1YearInstant2465000000JPY
Work in processCurrentQuarterInstant2248000000JPY
Raw materials and suppliesPrior1YearInstant4938000000JPY
Raw materials and suppliesCurrentQuarterInstant4520000000JPY
Other caPrior1YearInstant26006000000JPY
Other caCurrentQuarterInstant24362000000JPY
Allowance for doubtful accounts caPrior1YearInstant-930000000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-779000000JPY
Current assetsPrior1YearInstant882936000000JPY
Current assetsCurrentQuarterInstant900701000000JPY
Property plant and equipmentPrior1YearInstant119116000000JPY
Property plant and equipmentCurrentQuarterInstant122566000000JPY
GoodwillPrior1YearInstant1180000000JPY
GoodwillCurrentQuarterInstant1128000000JPY
Other iaPrior1YearInstant9996000000JPY
Other iaCurrentQuarterInstant9698000000JPY
Intangible assetsPrior1YearInstant11177000000JPY
Intangible assetsCurrentQuarterInstant10826000000JPY
Investment securitiesPrior1YearInstant89969000000JPY
Investment securitiesCurrentQuarterInstant92512000000JPY
Other ioaPrior1YearInstant38928000000JPY
Other ioaCurrentQuarterInstant38851000000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-410000000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-374000000JPY
Investments and other assetsPrior1YearInstant128487000000JPY
Investments and other assetsCurrentQuarterInstant130990000000JPY
Noncurrent assetsPrior1YearInstant258780000000JPY
Noncurrent assetsCurrentQuarterInstant264383000000JPY
AssetsPrior1YearInstant1141717000000JPY
AssetsCurrentQuarterInstant1165084000000JPY
Notes and accounts payable tradePrior1YearInstant664280000000JPY
Notes and accounts payable tradeCurrentQuarterInstant668050000000JPY
Income taxes payablePrior1YearInstant6355000000JPY
Income taxes payableCurrentQuarterInstant1481000000JPY
Provision for bonusesPrior1YearInstant6646000000JPY
Provision for bonusesCurrentQuarterInstant3172000000JPY
Provision for loss on anti monopoly act clPrior1YearInstant5475000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass